Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Imprimer: 0893-9675
ISSN En ligne: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v5.i2-3.100
pages 313-329

The c-erbB-2 Protein in Oncogenesis: Molecular Structure to Molecular Epidemiology

Paul W. Brandt-Rauf
Division of Environmental Sciences, Department of Medicine and Comprehensive Cancer Center, Columbia University, 60 Haven Avenue, New York, N.Y. 10032
Matthew R. Pincus
Department of Pathology, SUNY Health Sciences Center, 750 East Adams Street, Syracuse, N.Y. 13210
Walter P. Carney
Oncogene Sciences/ Applied Biotechnology, 80 Rogers Street, Cambridge, MA 01242

RÉSUMÉ

The c-erbB-2 (HER-2, neu) oncogene has been implicated frequently in many human tumors. This oncogene codes for a 185-kDa protein that functions as a transmembrane growth factor receptor. Overexpression of the normal protein or point mutations in the transmembrane domain of the protein have been shown to have a transforming effect. Molecular structure studies of the transmembrane domain provide a plausible explanation for this transforming effect in both cases and relate this to the process of receptor dimerization in the membrane, degradation of the protein with release of the extracellular domain (ECD) into the extracellular environment, and aberrant signal transduction. The release of the ECD into the extracellular environment provides a potential biomarker for the study of signal transduction at the molecular level in vivo. The ECD can be quantitated immunologically in the serum of individuals with cancers associated with p185 overexpression and in individuals at risk for the development of such cancers and can be used to distinguish these individuals from normal, healthy controls. Identification of such individuals by their serum ECD levels combined with specific chemotherapeutic/ chemoprophylactic interventions could allow for improvement treatment and prevention of c-erbB-2-related cancers.


Articles with similar content:

Oncogene- and Tumor-Suppressor Gene-Related Proteins in Plants and Fungi
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 1-2
Peter Loidl, Adele Loidl
Genetic Alterations in Liver Carcinogenesis: Implications for New Preventive and Therapeutic Strategies
Critical Reviews™ in Oncogenesis, Vol.11, 2000, issue 1
Francesco Feo, Maria R. De Miglio, Rosa M. Pascale, Maria M. Simile, Diego Calvisi, Maria R. Muroni
Transcriptional Targets of p53 That Regulate Cellular Proliferation
Critical Reviews™ in Eukaryotic Gene Expression, Vol.17, 2007, issue 1
Lakshmi Raj, Lauren Brown, Sam W. Lee, Sarah Boswell
Recurrent Fusion Oncogenes in Carcinomas
Critical Reviews™ in Oncogenesis, Vol.12, 2006, issue 3-4
Manuel R. Teixeira
Molecular Epidemiology of Human Cancer: Biomarkers of Genotoxic Exposure and Susceptibility
Journal of Environmental Pathology, Toxicology and Oncology, Vol.20, 2001, issue 4
Stephen G. Grant